ライフサイエンスコーパス: drug carrier

1 , thus making them promising candidates as a drug carrier.

2 GCF following its release from beta-TCP as a drug carrier.

3 delivery in bone with temperature-sensitive drug carriers.

4 n in vivo, indicating their potential use as drug carriers.

5 increase the exposure of tumor cells to ELP drug carriers.

6 conductors, cosmetics, microelectronics, and drug carriers.

7 mpatible and biomimetic materials as well as drug carriers.

8 rties, which may be relevant to their use as drug carriers.

9 ve gained substantial traction as biological drug carriers.

10 ly(lactic-co-glycolic acid) (PLGA) nanoscale drug carriers.

11 they can be solved by loading into nanoscale drug carriers.

12 iers are important criteria in the design of drug carriers.

13 are widely used in paints, coatings, and as drug carriers.

14 man-induced NSCs (hiNSC) as personalized NSC drug carriers.

15 r improve the therapeutic efficacy of EVs as drug carriers.

16 tions as efficient adsorbents, catalysts and drug carriers.

17 protocols relying on the use of liposomes as drug carriers.

18 e-permeabilizing agents and nanomaterials as drug carriers.

19 als become quenched upon being released from drug carriers.

20 rapeutics; however, GNPs have limitations as drug carriers.

21 effective exosome-based or exosome-mimicking drug carriers.

22 agents for magnetic resonance imaging and as drug carriers.

23 b) were evaluated as potential nutraceutical/drug carriers.

24 t uniquely position them as highly effective drug carriers.

25 pear preferable to those with solid cores as drug carriers.

26 ective cell interactions make them promising drug carriers.

27 g peptides (CPPs) are promising molecules as drug carriers.

28 lency and size tunability make them exciting drug carriers.

29 at rationale for the trend toward nano-sized drug carriers.

30 Nanoparticle drug carriers activated by focused ultrasound-remotely a

31 rget a temperature-responsive macromolecular drug carrier, an elastin-like polypeptide (ELP) to solid

32 ent cells respond differentially to the same drug carrier, an important factor that should be conside

33 rived FDA approved material (beeswax) as the drug carrier and fenofibrate as the drug.

34 tion that have been successfully employed as drug carriers and biomaterials in several applications.

35 possibilities for engineering of particulate drug carriers and biomedical platforms with tuneable com

36 cal blood flow and poor interactions between drug carriers and bone material.

37 mes have now progressed beyond simple, inert drug carriers and can be designed to be highly responsiv

38 tically evaluate the status of dendrimers as drug carriers and find answers as to why this class of c

39 sign of multifunctional hybrid materials, in drug carriers and gene delivery, as nanoreactors, or as

40 ew is focused on why EVs are such compelling drug carriers and how to release their fullest potential

41 se rates have on the efficacy of synergistic drug carriers and motivate the use of HA as a delivery p

42 be applied to multiple receptor targets and drug carriers and offers promising therapeutic benefits

43 eterogeneous transport behavior of submicron drug carriers and pathogens in biological environments.

44 he successful integration of CAR-NK cells as drug carriers and paves the way for combined cellular an

45 mide conjugates merit further development as drug carriers and radioimaging agents.

46 ly inject engineered ultrasound-controllable drug carriers and subsequently apply a novel two-compone

47 option for liver cancer using the radiopaque drug-carrier and micro-embolic agent Lipiodol, which has

48 rior performance in water purification, as a drug carrier, and in thermal insulation.

49 erials field for use as diagnostic reagents, drug carriers, and tissue engineering scaffolds.

50 Red blood cells (RBCs) based drug carrier appears to be the most appealing for protei

51 to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged activation o

52 In this approach, drug carriers are modified with targeting ligands that c

53 These drug carriers are passively targeted to tumors through t

54 Polymeric drug carriers are widely used for providing temporal and

55 S to analyze drug penetration of a liposomal drug carrier as well as its metabolites.

56 the potential application of hydrogel-based drug carriers as synthetic immune niche scaffolds for pr

57 discussed in this review, include serving as drug carriers, as targeting ligands, and as protease-res

58 for anchoring of drug conjugates and bulkier drug carriers, as well as proper signaling for uptake wi

59 The drug-carrier association after intravenous administratio

60 tion recently because of their simple use as drug carrier at human body temperature.

61 e other hand, development of multifunctional drug carriers at the 'nano'-scale is providing exciting

62 he importance of rapid drug release from the drug carriers at the tumor site.

63 thod describes advanced tailoring of polymer drug carriers based on polymer-block-peptides.

64 rm basis for the development of EVs as smart drug carriers based on straightforward and transferable

65 magnetic fields with the electric forces in drug-carrier bonds to enable remotely controlled deliver

66 hybrid nanogels in nanomedicine, not only as drug carriers but also as imaging and theranostic agents

67 how that eHNP-A1 not only serves as a stable drug carrier, but also has a therapeutic effect itself t

68 ata with CD44TA-SMP, we anticipate that this drug carrier can open new avenues in TB management.

69 of EVs to liposomes and vice versa, improved drug carriers can be developed which will advance the fi

70 f biomaterials into nanoscale and microscale drug carriers can facilitate targeted interactions with

71 The size and shape of nanoparticle (NP) drug carriers can potentially be manipulated to increase

72 g the utility of enzyme-responsive nanoscale drug carriers capable of targeted accumulation and reten

73 When used as a drug carrier, CaRA(EGFR) effectively delivers the toxin

74 s and binding epitopes must be accessible to drug carriers, carriers must be free of harmful effects,

75 ould be employed to model the release of any drug-carrier combination.

76 ET imaging to systematically investigate how drug-carrier compatibility affects drug release in a tum

77 these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing op

78 Here, we synthesized a nanoparticle-based drug carrier composed of chitosan, UA and folate (FA-CS-

79 ications ranging from waterborne coatings to drug-carrier-delivery systems.

80 This technology represents a novel drug carrier designed to prolong the presence of bioacti

81 Liposomes are clinically used drug carriers designed to improve the delivery of drugs

82 hile not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common

83 ering osteoarthritis (OA) therapies, yet how drug carriers distribute within the joint remains unders

84 achment of a targeting ligand to the drug or drug carrier does not enhance its brain biodistribution;

85 d other nano-sized constructs are attractive drug carriers due to their extended plasma circulation;

86 hase-transfer catalysts, and multifunctional drug carriers, each of which benefits from opposing surf

87 NF-kappaB) inflammatory cascade bound to the drug carrier elastin-like polypeptide (ELP), decreases N

88 nto the interactions between medical agents, drug carriers, emerging materials, and cells at the sing

89 ension, grafting of antioxidant molecules to drug carriers enables a dual-function mechanism to effec

90 nter-mucosal transport of food particulates, drug carriers, etc.

91 Furthermore, drug carriers face additional challenges in their transl

92 ment of solid tumors, systemically delivered drug carriers face significant challenges that are impos

93 We therefore developed a nanoscale drug carrier for antimicrobial codelivery by combining a

94 lipid matrix and nano-size make it an ideal drug carrier for brain targeting.

95 noparticles have increasingly been used as a drug carrier for cancer treatment due to their high abso

96 to test the usefulness of serum albumin as a drug carrier for corneal disorders.

97 rtcoming" can be advantageous when used as a drug carrier for directing therapy to NMIBC.

98 udy aims to evaluate foam as a potential new drug carrier for IPC delivery.

99 in this work extend the concept of a general drug carrier for loading both positively and negatively

100 A novel nanoparticle-based drug carrier for photodynamic therapy is reported which

101 y of non-ionic surfactants currently used as drug carriers for antibiotic, anti-inflammatory, and ant

102 of widely used surfactants currently used as drug carriers for antibiotic, anti-inflammatory, and ant

103 Ts are increasingly being explored as potent drug carriers for cancer treatment, for biosensing, and

104 esicles, or liposomes, have been employed as drug carriers for decades, resulting in several approved

105 and independently, especially when designing drug carriers for nose-to-brain drug delivery.

106 Silica nanoparticles (SiNPs) are promising drug carriers for ophthalmic drug delivery.

107 tial of using ceramic-based nanoparticles as drug carriers for photodynamic therapy has been demonstr

108 ants to amplify anti-tumor immune responses, drug carriers for targeted delivery of anticancer agents

109 ges by acting as both therapeutic agents and drug carriers for the remarkable treatment of skin cance

110 ncerous cells and, therefore, can be used as drug carriers for tumor therapy.

111 nhances tumor imaging, and the addition of a drug carrier function to the particles is envisioned.

112 Drug carriers generally fail to provide superior efficac

113 To determine if this class of drug carriers has potential applications in vivo, FSI/Ra

114 Various liposomal drug carriers have been developed to overcome short plas

115 To combat this, various drug carriers have been investigated to enhance the phar

116 While particulate drug carriers have been utilized to passively redirect l

117 y lacking therapy, in part because drugs and drug carriers have no natural endothelial affinity.

118 These novel inhalable silk-based drug carriers have the potential to be used as anti-canc

119 When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX)

120 dispensed for the potential that nano-sized drug carriers hold.

121 Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments

122 mulation of a thermally responsive polymeric drug carrier in solid tumors over a single heat-cool cyc

123 ) to enhance the penetration of nanoparticle drug carriers in convection-enhanced delivery (CED).

124 ' application as markers in diagnosis and as drug carriers in disease therapy.

125 DEAdcCE-caged peptide sequences as selective drug carriers in the context of photocontrolled targeted

126 cations of EVs as natural therapeutics or as drug carriers in the treatment of renal disorders and pr

127 required to utilize their full potential as drug carriers, including loading methods, in-depth chara

128 e the actual drug release kinetics from nano drug carriers inside the dialysis bag from the experimen

129 ntial in applications such as cell-cell/cell-drug carrier interaction studies and rapid screening of

130 e introduction of an additional mechanism of drug/carrier interaction.

131 ttempts were made to target microparticulate drug carriers into cytoplasm bypassing the endocytotic p

132 eficient the translation of these nano-sized drug carriers into the clinical setting is.

133 A modern multi-functional drug carrier is critically needed to improve the efficac

134 The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of th

135 ined photo-responsive tubisomes as potential drug carriers is evaluated.

136 However, their use as drug carriers is limited by biological (e.g., immunologi

137 fully capitalize on the potential of EVs as drug carriers, it is important to study and understand t

138 This strategy led to NC drug carriers loaded with tobramycin antibiotics and ant

139 rehydration, blood products, and nutrition), drug carriers, maintenance fluids, and fluids for techni

140 last-targeting peptide ligands and nanoscale drug carriers may be translated into clinical applicatio

141 A novel anti-cancer drug carrier, mesenchymal stem cells (MSCs) encapsulatin

142 -isopropylacrylamide) (PNIPAm), as a general drug carrier model for controlled drug release.

143 ate endohedral complexes as superconductors, drug carriers, molecular reactors, and ferroelectric mat

144 Vascular-targeted drug carriers must localize to the wall (i.e., marginate

145 into consideration, our model independent of drug carrier not only enables the proper interpretation

146 o-electric nanoparticles as field-controlled drug carriers offer a unique capability of field-trigger

147 routinely used as a surfactant to formulate drug carriers, on the transport of nanoparticles in fres

148 at hydrophobin might be a powerful tool as a drug carrier or a pH sensitive drug-release compound.

149 In an attempt to develop such a multi-drug carrier, our work focuses on functional multimodal

150 or loading RNA into EVs, their advantages as drug carriers over synthetic-lipid-based systems, and th

151 e quantum rattles significantly enhanced the drug-carrier performance of the silica shell.

152 etism of gold quantum dots, and enhances the drug-carrier performance of the silica shell.

153 s silica nanoparticles (SiNPs) are promising drug carrier platforms for intraocular drug delivery.

154 We encapsulated the drug carrier pPB-HSA, which specifically binds to the PD

155 hly express the PDGFbeta-receptor, using the drug carrier pPB-MSA.

156 Inorganic nanoparticles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, and

157 In conclusion, the development of an "ideal" drug carrier should involve the optimization of both dru

158 These multimodal nanocomposite drug carriers should be ideal for selective intra-arteri

159 control the intratumor distribution of these drug carriers should improve vascular-specific delivery.

160 Ideal drug carriers should not only rapidly diffuse across muc

161 the application of chitosan as an anticancer drug carrier such as tamoxifen, doxorubicin, paclitaxel,

162 Nanoparticulate drug carriers such as liposomal drug delivery systems ar

163 nd therapeutic cells, as well as alternative drug carriers such as nanoparticles.

164 We demonstrated that relatively large drug carriers, such as 200-nm liposomes, can also be del

165 abolically active Lactobacillus reuteri as a drug carrier suitable for oral administration.

166 st, stable, biocompatible and cost-effective drug carrier system with high encapsulation efficiency.

167 sub-cellular level is a desired feature of a drug carrier system.

168 Specifically, multi-drug carrier systems and functional NMOFs exhibiting dua

169 It offers many advantages over other drug carrier systems, including ease of manufacturing an

170 very of antibiotics with novel biodegradable drug carrier systems, such as the gentamicin-collagen im

171 nds (e.g., enzymes, antibodies, peptides) to drug carrier systems.

172 An example is drug carriers targeted to endothelial barriers, which ca

173 abilized immunoliposomes (anti-HER2 SL) as a drug carrier targeting HER2-overexpressing cancers.

174 indicate that HL6 could be a more efficient drug carrier than L6 for biomedical as well as biotechno

175 the first time as a magnetically responsive drug carrier that can serve both as a magnetic resonance

176 A new micelle drug carrier that consists of a diblock polymer of propy

177 le and highlight the advantages of a natural drug carrier that demonstrates reduced cellular toxicity

178 erum albumin (HSA) is a clinically validated drug carrier that improves drug delivery to tumor tissue

179 ncirculating, biodegradable s.c. implants as drug carriers that are stable throughout the duration of

180 These challenges signify an unmet need for drug carriers that can cross the BBB and deliver drugs t

181 There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to

182 There is an unmet need for easy-to-visualize drug carriers that can deliver therapeutic cargoes deep

183 improve the delivery of existing drugs with drug carriers that can manipulate when, where, and how a

184 ved platelets can serve as immune-compatible drug carriers that interact with and deliver drugs to ca

185 Here we apply drug carriers that leverage electrostatic interactions w

186 and self-quenching; consequently, efficient drug carriers that overcome these obstacles are urgently

187 systems is hampered by the lack of suitable drug carriers that respond sharply to visible light stim

188 promising applications as imaging probes and drug carriers that target cancer cells for cytoplasmic c

189 When designing drug carriers, the drug-to-carrier ratio is an important

190 variable fragments (scFvs) hold potential as drug carriers, their application in ADCs has been limite

191 amer-conjugated multistage vector (ESTA-MSV) drug carrier to bone marrow for the treatment of breast

192 anotechnology-based approach that utilizes a drug carrier to deliver a therapeutic cargo specifically

193 elf-assembling protein, was first applied as drug carrier to stabilize GLP-1 against protease degrada

194 suggests that HALs may be a useful targeted drug carrier to treat CD44-expressing tumors.

195 are coated onto balloons using excipients as drug carriers to facilitate adherence and release of dru

196 to the necessity of developing site-specific drug carriers to improve the delivery of molecular medic

197 To develop drug carriers to macrophages, it is important to underst

198 ifically Metal-Organic Frameworks (MOFs), as drug carriers to overcome these limitations.

199 ight into the development of new transdermal drug carriers to treat a variety of skin disorders.

200 h as gene targeting vectors and encapsulated drug carriers (typical range, 100-300 nm) into tumors.

201 tro studies using tumor cells to investigate drug-carrier uptake and destruction of cancer cells by p

202 ng direct periadventitial delivery without a drug carrier was published prior to 2000.

203 d polymeric (~10 nm) and liposomal (~100 nm) drug carriers were administered to mice with resistant a

204 both small dye molecules and large liposomal drug carriers were quantified using fluorescence microsc

205 Nanoparticles or drug carriers which can selectively bind to cells expres

206 aim of this work was to develop a nanoscale drug carrier, which could be loaded with an anti-cancer

207 h outlined here uses nanoparticle (NP)-based drug carriers, which have unique properties that enhance

208 model for optimizing the pharmacokinetics of drug carriers who's circulatory half-life is dependent i

209 density nature of most biomaterials used as drug carriers will result in very low fractions of the a

210 Developing a drug carrier with favorable handling characteristics tha

211 on and applicable to fabricating particulate drug carriers with desired size and shape.

212 tool that has facilitated the development of drug carriers with enhanced penetration of mucus, brain

213 ng avenues for the design of multifunctional drug carriers with extreme control over their physico-ch

214 The first sequence aggregates drug carriers with millimeter-precision by orders of mag

215 cent advances achieved by combining drugs or drug carriers with NIR light responsive plasmonic nanoma

216 capsule engineering can lead to well-defined drug carriers with unique properties (139 references).

217 n in the mouse stomach compared with passive drug carriers, with no apparent toxicity.